These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1455361)

  • 1. [The use of Capoten in systemic scleroderma].
    Guseva NG; Anikina NV; Shcherbakov AB
    Ter Arkh; 1992; 64(5):100-2. PubMed ID: 1455361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].
    Madsen JL; Hvidt S
    Ugeskr Laeger; 1984 Sep; 146(36):2695-7. PubMed ID: 6393495
    [No Abstract]   [Full Text] [Related]  

  • 5. Captopril in the treatment of scleroderma renal crisis.
    Thurm RH; Alexander JC
    Arch Intern Med; 1984 Apr; 144(4):733-5. PubMed ID: 6370160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of renal crisis in progressive systemic sclerosis with captopril].
    Latorre LC; Mion D; Zerbini CA; Pastor EH; Resende C; Fidelis TS; Gabriel Júnior A; Assad RL; Cossermelli W
    Rev Hosp Clin Fac Med Sao Paulo; 1985; 40(1):18-21. PubMed ID: 3903950
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of captopril to reverse the renal crisis of scleroderma.
    Brown EA; Macgregor GA; Maini RN
    Ann Rheum Dis; 1983 Feb; 42(1):52-3. PubMed ID: 6338841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's phenomenon and scleroderma.
    Harper FE; LeRoy EC
    Compr Ther; 1981 Feb; 7(2):45-51. PubMed ID: 6163587
    [No Abstract]   [Full Text] [Related]  

  • 15. [Intra-arterial reserpine in Raynaud's disease and syndrome].
    Arcas Meca R; Ono Okabe S; Barroso-Moguel R; Quijano Pitman F
    Arch Inst Cardiol Mex; 1972; 42(2):260-8. PubMed ID: 5028993
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
    Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
    Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recuperation of the renal function with early use of captopril in sclerodermal renal crisis].
    Lizasoain M; Martínez R; Fernández R; García-Díaz JD; Bello I; Praga M
    Med Clin (Barc); 1988 Nov; 91(15):586-8. PubMed ID: 3067015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.